Please check your internet connection and try again.
# Nandrolone Decanoate (deca-Durabolin)
## Overview
Nandrolone decanoate is a synthetic anabolic-androgenic steroid (AAS) derived from testosterone. It exhibits significant anabolic activity with reduced androgenic potential compared to testosterone. It is an injectable ester with a long duration of action due to slow release from the intramuscular depot.
## Primary Indications
* Management of the anemias of renal insufficiency (off-label use, historical primary indication).
* Adjunctive therapy in senile and postmenopausal osteoporosis.
* Protein-sparing agent in severe catabolic states (e.g., major surgery, severe trauma).
## Adult Dosing
* **Anemias of Renal Insufficiency:** 100 mg/week in men; 50–100 mg/week in women.
* **Osteoporosis/Catabolic States:** 50 mg every 3 to 4 weeks.
* *Note:* Dosing is highly variable and depends on local institutional protocols and therapeutic response; there is no standardized "maximum" dose, but supraphysiological doses carry significant risks.
## Pediatric Dosing
* **Renal Anemia:** 1–1.5 mg/kg once weekly.
* *Note:* Use in children is restricted due to the risk of premature epiphyseal closure and sexual precocity. Strict monitoring by a pediatric endocrinologist is required.
## Dose Adjustments
* **Hepatic Impairment:** Avoid use; contraindicated in patients with severe liver disease.
* **Renal Impairment:** Use with caution; monitor for fluid retention and hyperphosphatemia.
## Contraindications
* Known hypersensitivity to nandrolone.
* Carcinoma of the male breast.
* Carcinoma of the prostate (suspected or known).
* Pregnancy (Category X: risk of virilization of female fetus).
* Nephrosis or the nephrotic phase of nephritis.
* Severe hepatic impairment.
## Adverse Effects
* **Endocrine:** Virilization in women (hirsutism, deepening of voice, menstrual irregularities), gynecomastia in men, premature epiphyseal closure in children.
* **Cardiovascular:** Dyslipidemia (decreased HDL, increased LDL), fluid retention, hypertension, increased risk of left ventricular hypertrophy.
* **Hepatic:** Peliosis hepatis, hepatocellular adenoma, cholestatic jaundice.
* **Psychiatric:** Mood swings, aggression, dependency/abuse potential.
## Key Drug Interactions
* **Anticoagulants:** May increase sensitivity to oral anticoagulants (e.g., warfarin); monitor INR closely.
* **Insulin/Hypoglycemic agents:** May decrease blood glucose levels; dosage adjustments for insulin or oral agents may be necessary.
* **Corticosteroids:** Concomitant use may increase the risk of edema, particularly in patients with cardiac or hepatic disease.
## Monitoring
* **Baseline/Periodic:** Liver function tests (LFTs), lipid profile, hematocrit/hemoglobin (polycythemia risk), and prostate-specific antigen (PSA) in men.
* **Pediatric:** Serial hand/wrist radiographs to monitor bone age and epiphyseal closure.
## Clinical Pearls
* **Abuse Potential:** Classified as a Schedule III controlled substance due to high potential for misuse in bodybuilding and athletic performance enhancement.
* **Half-life:** The decanoate ester provides a sustained release, resulting in a prolonged half-life (approx. 6–12 days).
* **Efficacy:** Its use in modern medicine has declined significantly due to the availability of safer, more targeted therapies (e.g., erythropoiesis-stimulating agents for renal anemia).
* **Injection Technique:** Administer via deep intramuscular injection into the gluteal muscle.
***
*Disclaimer: This information is for educational purposes only. Prescribing practices and clinical protocols vary by jurisdiction and institution. Always verify specific dosages, contraindications, and drug interactions with current, local prescribing information (e.g., the manufacturer's package insert or official pharmacopeia) before administration.*
